BTG buys rival for $242M

The UK's BTG has announced plans to acquire Biocompatibles for £177 million, or about $242 million. With the acquisition, BTG gains access to Biocompatibles' oncology products, which include drug coated beads used to treat liver cancer, according to the Financial Times. BTG plans on investing heavily in Biocompatibles' products and development pipeline, the company said in a statement. Report

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.